Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
第一作者:
Alice,Indini
第一单位:
Department of Internal Medicine, Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milano, Italy.
作者:
主题词
动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯咪唑类(Benzimidazoles);氨甲酸酯类(Carbamates);人类(Humans);黑色素瘤(Melanoma);点突变(Point Mutation);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);皮肤肿瘤(Skin Neoplasms);磺胺类(Sulfonamides);存活率(Survival Rate)
DOI
10.1080/14740338.2020.1817376
PMID
32857940
发布时间
2022-04-17
- 浏览1

Expert opinion on drug safety
1229-1236页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文